

16 May 2017

### **Appointment of Independent Non-Executive Director**

Anteo Diagnostics Limited (ASX:ADO) today announced the appointment of Mr Alan Studley as an independent non-executive director.

Mr Studley has held various senior management roles in his career and has more than 30 years' experience as a director of public, private and not-for-profit organisations spanning a diverse range of industries. These include public health, media and communications, superannuation, manufacturing and technology. His roles include Executive Chairman of Revenue Clearing House Pty Ltd; Chief Operating Officer of Sausage Software Ltd; Executive Director of Women's and Children's Healthcare Network; Chief Executive Officer of Point Nepean Community Trust; Group Finance Director of HDM Mattingly Pty Ltd.

He is currently a non-executive director of Access Health and ANZGITA (Australian and New Zealand Gastroenterological International Training Association) and has previously held directorships with Health Super, Metropolitan Ambulance Service, Sausage Software, Methodist Ladies' College, Melbourne and other not-for-profit entities.

Mr Studley holds a Master of Business Administration, is a Fellow of the Australian Institute of Company Directors and a Fellow of CPA Australia.

The Chairman of Anteo, Dr John Hurrell, said "Alan brings extensive financial and operational management along with Board experience gained from a wide range of industries including health, manufacturing and technology and has a deep understanding of governance. We are pleased to welcome Alan to the Board and believe that with his broad governance experience, he will make an immediate and valuable contribution to the Board. In addition, I have asked Alan to assume the role of Chairman of the Audit and Risk Committee. I thank Richard Martin for his work previously in this position and he will remain one of the Committee members."

Mr Studley said that he looked forward to working with his fellow Anteo directors, particularly in supporting and contributing to the important work commenced by Chairman Dr John Hurrell.

### **ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries**

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical

diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high- value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit [www.anteodx.com](http://www.anteodx.com)